4.8 Article

NPCDR: natural product-based drug combination and its disease-specific molecular regulation

Journal

NUCLEIC ACIDS RESEARCH
Volume 50, Issue D1, Pages D1324-D1333

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/nar/gkab913

Keywords

-

Funding

  1. National Natural Science Foundation of China [U1909208, 81872798, 82022075, 81874380, 82104207]
  2. Natural Science Foundation of Zhejiang Province [LR21H300001, LR18H160001]
  3. Leading Talent of `Ten Thousand Plan' -National High-Level Talents Special Support Plan of China
  4. Fundamental Research Fund for Central University [2018QNA7023]
  5. Key R&D Program of Zhejiang Province [2020C03010]
  6. Double Top-Class University Project [181201*194232101]
  7. Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare
  8. Alibaba Cloud
  9. Information Technology Center of Zhejiang University

Ask authors/readers for more resources

Natural products have a long history in drug discovery and are now being combined with other therapeutic strategies. The newly developed NPCDR database provides comprehensive information on NP-based drug combinations and disease-specific molecular regulation data. It is expected to have great implications for network pharmacology, medical biochemistry, drug design, and medicinal chemistry.
Natural product (NP) has a long history in promoting modern drug discovery, which has derived or inspired a large number of currently prescribed drugs. Recently, the NPs have emerged as the ideal candidates to combine with other therapeutic strategies to deal with the persistent challenge of conventional therapy, and the molecular regulation mechanism underlying these combinations is crucial for the related communities. Thus, it is urgently demanded to comprehensively provide the disease-specific molecular regulation data for various NP-based drug combinations. However, no database has been developed yet to describe such valuable information. In this study, a newly developed database entitled 'Natural Product-based Drug Combination and Its Disease-specific Molecular Regulation (NPCDR)' was thus introduced. This database was unique in (a) providing the comprehensive information of NP-based drug combinations & describing their clinically or experimentally validated therapeutic effect, (b) giving the disease-specific molecular regulation data for a number of NP-based drug combinations, (c) fully referencing all NPs, drugs, regulated molecules/pathways by cross-linking them to the available databases describing their biological or pharmaceutical characteristics. Therefore, NPCDR is expected to have great implications for the future practice of network pharmacology, medical biochemistry, drug design, and medicinal chemistry. This database is now freely accessible without any login requirement at both official (https://idrblab.org/npcdr/) and mirror (http://npcdr.idrblab.net/) sites.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available